Gleg PLC的新测试方法改进了对使用Osimertinib的肺癌病人的治疗耐药性的早期检测。 Angle PLC's new test method improves early detection of treatment resistance in lung cancer patients using osimertinib.

使用AstraZeneca's osimertinib治疗的非小型细胞肺癌患者的循环肿瘤细胞(CTCs)和肿瘤DNA(ctDNA)的循环性DNA(ctDNA)分析新方法, Angle PLC has released research on a new method for analyzing circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in non-small cell lung cancer patients treated with AstraZeneca's osimertinib. 这种双重分析技术使用Parsortix系统,发现抗药性突变和DNA变化的患者多于单一分析方法。 This dual analysis technique, using the Parsortix® system, identified more patients with resistance mutations and DNA changes than single analysis methods. 这有助于及早发现治疗耐药性,改善临床试验的病人分层。 This could help in early detection of treatment resistance and improve patient stratification for clinical trials.